TrialBMC cancer2022

Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial.

Yoshimasa Shiraishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.